BHI to form Commercial Relevance Advisory Board
BHI, which focuses on commercializing new biomedical innovations and increasing access to early-stage development funding in central Maryland, announced that it will form the Commercial Relevance Advisory Board. CRAB members were selected to represent a diverse cross-selection of academic organizations and business enterprises.
Members come from throughout central Maryland and include venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland, Johns Hopkins University, and several leading biotechnology companies.
CRAB plans to assist BHI in evaluating market research and product development opportunities in central Maryland, as well as to assist in determining whether emerging entrepreneurs, companies, and their science and technology have potential for commercial applications.
BHI plans to utilize feedback from CRAB members as part of its due diligence process and in establishing a formal client relationship for potential future investment. BHI says that it hopes to transform central Maryland into a leading BioHealth entrepreneurial and commercial hub within the next five years.
CRAB members will also include representatives from Emergent BioSolutions, Inc., Intrexon, NaviMed, Howard Hughes Medical Institute, Chukujee Therapeutics and Vaxin, Inc.